← Evidence map

TrialBritish journal of cancer2026

Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7.

Theodoros Papathanasiou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7. | OpenQuestion